2. Variable doses of target of rapamycin inhibitors (TOR‐I) and calcineurin inhibitors (CNI) and lower versus higher doses of TOR‐I: subgroup analysis of study methodology and design features for all acute rejection.
| Variable | Variable doses of TOR‐I and CNI* | Lower versus higher doses of TOR‐I** | ||||
| Studies | RR (95% CI) | P‐value for subgroup differences | Studies | RR (95% CI) | P‐value for subgroup differences | |
| Publication type | ||||||
| Abstract | 2 | RR 0.85 (95% CI 0.50 ‐ 1.46) | 0.7 | 0 | No studies | Not applicable |
| Journal | 7 | RR 0.83 (95% CI 0.63 ‐ 1.08) | 13 | (RR 1.24, 95% CI 1.10 to 1.41) | ||
| Risk of bias | ||||||
| Low risk | 2 | RR 0.85 (95% CI 0.50 ‐ 1.46) | 0.81 | 5 | (RR 1.33, 95% CI 1.15 to 1.55) | 0.10 |
| High or unclear risk | 7 | RR 0.79 (95% CI 0.59 ‐ 1.06) | 8 | (RR 1.06, 95% CI 0.84 to 1.33) | ||
| CNI co‐intervention | ||||||
| Tacrolimus | 5 | RR 0.77 (95% CI 0.51 ‐ 1.16) | 0.67 | 3 | (RR 1.62, 95% CI 1.19 to 2.19) | 0.06 |
| Cyclosporin | 4 | RR 0.85 (95% CI 0.64 ‐ 1.14) | 9 | (RR 1.17, 95% CI 1.02 to 1.35) | ||
| Antibody induction | ||||||
| No induction | 6 | RR 0.72 (95% CI 0.53 ‐ 0.98) | 0.97 | 10 | (RR 1.25, 95% CI 1.09 to 1.45) | 0.81 |
| Antibody induction | 3 | RR 1.01 (95% CI 0.69 ‐ 1.46) | 3 | (RR 1.20, 95% CI 0.90 to 1.62) | ||
| TOR‐I | ||||||
| Everolimus | 2 | (RR 0.93, 95% CI 0.65 to 1.32) | 0.4 | 7 | (RR 1.11, 95% CI 0.93 to 1.33) | 0.09 |
| Sirolimus | 7 | (RR 0.75, 95% CI 0.55 to 1.03) | 6 | (RR 1.39, 95% CI 1.16 to 1.66) | ||
* Includes 9 studies, which reported the outcome of all acute rejection
** Includes 13 studies, which reported the outcome of all acute rejection